NU6102 is a potent CDK1 and CDK2 inhibitor with IC50 of 9.5 nM and 5.4 nM against CDK1/cyclinB and CDK2/cyclinA3 respectively.
NU6102 exhibits synergistic growth inhibition, and enhanced cytotoxicity in HT29 cells in vitro and HT29 tumour growth inhibition in vivo combined with Pictilisib.
NU6102 induces G2 arrest, inhibition of Rb phosphorylation and cytotoxicity in SKUT-1B cells (LC50=2.6 uM, for a 24h exposure).
